{
    "2020-09-22": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial",
                "features": {
                    "keywords": [
                        "investigational",
                        "once-weekly",
                        "insulin icodec",
                        "efficacious",
                        "well-tolerated",
                        "type 2 diabetes",
                        "phase 2 trial"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}